Sanofi announces that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. This acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities.
Read the full article: Sanofi Completes the Acquisition of Dynavax //
Source: https://www.globenewswire.com/news-release/2026/02/10/3235419/0/en/Press-Release-Sanofi-completes-the-acquisition-of-Dynavax.html